Compare NBY & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | NXTC |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 35.9M |
| IPO Year | 2007 | 2019 |
| Metric | NBY | NXTC |
|---|---|---|
| Price | $1.95 | $12.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 764.8K | 33.3K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | $370,000.00 | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.31 |
| 52 Week High | $19.95 | $15.74 |
| Indicator | NBY | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 63.93 |
| Support Level | $1.01 | $10.73 |
| Resistance Level | $2.52 | $14.01 |
| Average True Range (ATR) | 0.26 | 1.08 |
| MACD | 0.11 | 0.30 |
| Stochastic Oscillator | 96.45 | 86.45 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.